Exelixis Q3 revenues $597.8M, EPS $0.69; announces $750M stock buyback by 2026

EXELIXIS, INC.

2025-Q3 EPS reported $1.90 revenue$1,721,463,000

Total revenues $597.8M (+10.8% YoY); cabozantinib US net product rev $542.9M (+13.5% YoY).
GAAP diluted EPS $0.69 (vs $0.40); Non-GAAP diluted EPS $0.78 (vs $0.47).
Board authorized $750M stock repurchase program through Dec 31, 2026.
Restructuring charges $19.8M related to corporate reorganization; plan to close King of Prussia office.
Zanzalintinib NDA submission planned before year-end based on positive STELLAR-303 colorectal cancer data.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.